LQDA Stock Rockets 40% Today – BTIG Calls United Therapeutics Settlement ‘Better Than Best-Case Scenario’
LifeSci Capital said the agreement removes a major obstacle that could have discouraged potential buyers from pursuing an acquisition of Liquidia. BTIG upgraded Liquidia to ‘Buy’ from ‘Neutral’ with a $70 price target, implying about 93% upside from current levels. Wells Fargo raised its target to $33 from $30 while keeping an ‘Equal Weight’ rating. … Read more